CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Ohio Innovation Fund

Bill Baumel, Managing Director

Surviving & Thriving During A Pandemic

Bill Baumel

Bill Baumel

At a post-9/11, 2001 investment conference, a company CEO presented a singleslide deck — a picture of a train wreck. Sequoia released an infamous investment memo at the start of the ’08-’09 financial crisis. The key takeaway? “The world has ended.” In March of 2020, Sequoia released another memo following similar talking points. “No, really this time, the world has ended.” So, why do I have renewed hope for innovation and startups despite the effects of COVID-19?


I was investing in Silicon Valley post-9/11 and during the Great Recession, and what I saw was companies hoping to fit into one of two buckets: Survive or Thrive — and to avoid the dreaded third bucket of Perish.


Companies that I invested in during ‘01-’02 and ’08-’09 went on to become some of the most successful I’ve worked with, including several what are now called unicorns ranging in exit value from a few billion to over $30 billion. Why have hope now? Because I see the same potential for exceptional companies to grow within the current COVID-19 environment.


First, seek to thrive – create a new business model or pivot/optimize your existing business model to one that provides a must-have solution within the pandemic, and for what the world will likely look like post this time period.


If you cannot thrive today, but it’s likely that as the height of the pandemic passes things should improve — seek to survive. Preserve the core of your existing business and whichever team members are absolutely critical for your startup to weather this storm.


Take two Ohio Innovation Fund portfolio company examples of thriving: Aware is a collaboration management and monitoring tool for next-generation collaboration platforms such as Workplace by Facebook, Microsoft Teams, Yammer, and Slack. In the onset of “Stay at Home” orders across the United States in mid-March, the company saw more demand for its product in 45 days than it had in all of 2019. Aware was positioned to lead the shift to remote work and risk management, which was initially forecast to progress over 3-5 years. With COVID-19, the shift accelerated and was a necessity overnight, and Aware leveraged their technology to accommodate the rapidly increasing demand.


ScriptDrop is a prescription delivery service partnered with Kroger, Albertsons, Publix, RiteAid, Giant Eagle, and thousands of independent pharmacies across the United States. As COVID began to spread, demand for safe, contactless prescription delivery skyrocketed. The ScriptDrop team sprang into action and accomplished one and a half years of product development in the span of two months in order to satisfy demand.


 


 


I don’t mean to suggest that there hasn’t been or won’t continue to be incredible stress, however, diamonds are only formed under extreme pressure. While everyone is feeling this strain, there are several positives in the current environment similar to those in past crises:


1) Talent is more available — Hiring top talent is much easier in a downturn as many companies are cutting costs across the board, including laying off employees with high impact and potential. Now is a great time to build or improve your core team.


2) The gift of time — Time to think, plan, hire, connect, and build a strong stakeholder network for your company with less distractions due to the environment we find ourselves in. Take advantage of the most valuable commodity you have — time.


 3) Value creation efficiency — The biggest bang for your buck in terms of a dollar invested to dollar created happens during downturns. Unnecessary marginal spending goes away thanks to a renewed commitment to getting more done with less, and importantly, out of the box, breakthrough thinking is at a high point. Tough circumstances bring out the best in human ingenuity and creativity.


This economic downturn is starkly different than those previously experienced by the US as a result of significant underlying economic issues — for example, the tech and housing bubbles. In this case, there is no fundamental economic issue, pushing us into uncharted territory with the exact ways the world will be impacted post-COVID-19 yet to be fully determined.


Overall, this pandemic has brought to light the inefficiencies and challenges inherent in our current systems, and adversity could become an opportunity if we can find solutions that will better prepare us for whatever the future will bring.


You can see this economic downturn as the world ending or a more innovative world just beginning.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biotech-startups.lifesciencesreview.com/leadership-perspective/surviving-thriving-during-a-pandemic-nwid-422.html